Table 3. Gene promoter methylation status by matching factors and case characteristics.
| Gene | Overall | Black | White | |||
|---|---|---|---|---|---|---|
|
|
|
|
||||
| OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | |
| 1–4-Yr followup: | ||||||
| MGMT | 0.66 (0.32–1.38) | 0.270 | 0.90 (0.32–2.51) | 0.836 | 0.44 (0.15–1.29) | 0.134 |
| APC | 0.85 (0.53–1.38) | 0.515 | 0.83 (0.42–1.65) | 0.597 | 0.93 (0.47–1.86) | 0.841 |
| RARB | 1.74 (1.06–2.87) | 0.029 | 1.89 (0.93–3.84) | 0.078 | 1.68 (0.83–3.41) | 0.147 |
| CCND2 | 0.77 (0.34–1.75) | 0.528 | 2.14 (0.55–8.40) | 0.275 | 0.36 (0.11–1.25) | 0.107 |
| RASSF1 | 0.72 (0.42–1.24) | 0.239 | 0.44 (0.17–1.15) | 0.093 | 0.97 (0.49–1.92) | 0.938 |
| 4–15-Yr followup: | ||||||
| MGMT | 0.71 (0.36–1.38) | 0.312 | 1.44 (0.39–5.31) | 0.580 | 0.55 (0.25–1.23) | 0.148 |
| APC | 1.47 (0.91–2.37) | 0.119 | 2.45 (1.08–5.54) | 0.032 | 1.13 (0.61–2.11) | 0.698 |
| RARB | 1.66 (1.05–2.60) | 0.029 | 2.53 (1.30–4.91) | 0.006 | 1.06 (0.56–2.03) | 0.856 |
| CCND2 | 1.19 (0.54–2.61) | 0.658 | 1.46 (0.41–5.26) | 0.562 | 1.05 (0.38–2.90) | 0.920 |
| RASSF1 | 0.90 (0.55–1.47) | 0.679 | 1.42 (0.61–3.32) | 0.414 | 0.73 (0.39–1.34) | 0.304 |
| Age less than 65: | ||||||
| MGMT | 0.82 (0.40–1.65) | 0.572 | 0.80 (0.21–2.97) | 0.736 | 0.83 (0.36–1.91) | 0.665 |
| APC | 1.02 (0.62–1.65) | 0.950 | 0.84 (0.40–1.79) | 0.658 | 1.15 (0.61–2.20) | 0.663 |
| RARB | 1.73 (1.10–2.74) | 0.018 | 2.17 (1.15–4.10) | 0.017 | 1.35 (0.69–2.62) | 0.378 |
| CCND2 | 0.46 (0.18–1.19) | 0.110 | 0.82 (0.17–4.04) | 0.807 | 0.32 (0.09–1.10) | 0.070 |
| RASSF1 | 0.88 (0.53–1.46) | 0.621 | 0.85 (0.36–2.00) | 0.713 | 0.89 (0.47–1.67) | 0.712 |
| Age 65 or greater: | ||||||
| MGMT | 0.63 (0.32–1.25) | 0.188 | 1.35 (0.50–3.69) | 0.554 | 0.27 (0.09–0.82) | 0.020 |
| APC | 1.20 (0.75–1.92) | 0.447 | 2.08 (0.97–4.46) | 0.059 | 0.82 (0.43–1.54) | 0.529 |
| RARB | 1.52 (0.93–2.47) | 0.096 | 2.15 (1.00–4.60) | 0.049 | 1.15 (0.59–2.22) | 0.680 |
| CCND2 | 1.29 (0.60–2.76) | 0.510 | 2.67 (0.71–10.01) | 0.144 | 0.83 (0.30–2.29) | 0.715 |
| RASSF1 | 0.80 (0.47–1.35) | 0.402 | 1.00 (0.41–2.44) | 0.998 | 0.73 (0.37–1.43) | 0.357 |
| Low grade tumor: | ||||||
| MGMT | 0.75 (0.43–1.30) | 0.301 | 1.51 (0.56–4.07) | 0.418 | 0.53 (0.26–1.06) | 0.074 |
| APC | 0.85 (0.58–1.26) | 0.419 | 1.05 (0.58–1.90) | 0.866 | 0.71 (0.42–1.21) | 0.210 |
| RARB | 1.63 (1.09–2.42) | 0.017 | 2.54 (1.37–4.73) | 0.003 | 1.16 (0.67–1.99) | 0.597 |
| CCND2 | 1.10 (0.56–2.13) | 0.788 | 1.55 (0.55–4.34) | 0.409 | 0.85 (0.35–2.10) | 0.730 |
| RASSF1 | 0.85 (0.56–1.28) | 0.436 | 0.91 (0.47–1.76) | 0.774 | 0.80 (0.47–1.36) | 0.412 |
| High grade tumor: | ||||||
| MGMT | 0.56 (0.21–1.54) | 0.262 | 0.65 (0.16–2.74) | 0.561 | 0.44 (0.10–1.83) | 0.258 |
| APC | 2.43 (1.20–4.90) | 0.014 | 3.21 (1.06–9.75) | 0.040 | 2.04 (0.80–5.18) | 0.133 |
| RARB | 1.55 (0.88–2.74) | 0.132 | 1.64 (0.76–3.52) | 0.207 | 1.40 (0.59–3.31) | 0.439 |
| CCND2 | 0.73 (0.25–2.09) | 0.558 | 3.87 (0.41–36.35) | 0.237 | 0.29 (0.06–1.38) | 0.118 |
| RASSF1 | 0.73 (0.35–1.50) | 0.389 | 0.67 (0.16–2.92) | 0.597 | 0.85 (0.37–1.95) | 0.707 |
*Adjusted for PSA and HGPIN at baseline.